Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries

July 7, 2021 12:21:36
  • Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers
  • With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits
  • TumorGenesis will use its GMP lab to produce its proprietary media that tricks tumor cells into growing outside the body the same as inside the body in addition to producing proteins and other biological products used in diagnosing, treating, and modifying tumor cells
On the heels of raising $21.34 million and three of its companies participating in the popular Biotechnology Innovation Organization (“BIO”) conference, Predictive Oncology (NASDAQ: POAI) continued its busy month with more substantive developments from its subsidiaries. The Minneapolis-based company, which develops and offers a suite of products and services across its portfolio companies focused on drug development and targeted cancer treatments, announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new GMP (good manufacturing practices) laboratories ( From its facilities in Birmingham, Alabama, Soluble Biotech specializes in formulation solutions and stability services used for vaccines, monoclonal antibodies, and biologics. The GMP facility ramps up these services so the company can rapidly provide clinical-trial-ready formulations to its customers. Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to “significantly increase [the company’s] potential customer base and lead to multiple long-term collaborations.” Interestingly, the lab news arrived less than two weeks after the BIO conference, an event that typically leads to dozens of proposal requests for Soluble Biotech’s services, even before the expanded offerings ( The lab will also be used to produce the proprietary media used in Soluble Biotech’s chromatography kits. The kits are used by pharmaceutical and biotechnology companies for highly selective removal of endotoxins, toxins inside bacterial cells released upon cell disintegration, as part of the final purification process ahead of clinical or animal studies. Headquartered in the biotech hotbed of Salem, Massachusetts, TumorGenesis will use its new lab to produce media as well, amongst other things. The company’s unique media tricks cancer cells, more specifically cancer and breast cancer cells, into acting in a petri dish (ex-vivo, outside the body) just like they would in vivo (inside the body). In this way, the cells can be tested to help oncologists make better informed decisions on what treatment may improve patient outcomes. The media can also be used in cancer cell editing to produce proteins and other biological products used in diagnosing, treating, and modifying tumor cells. The lab is a synergistic addition to TumorGenesis’ mission to advance leading edge personalized cancer medicine and drug discovery methods. According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that “[TumorGenesis] will be able to meet the needs of researchers who are exploring ways to use the cancer cell’s own mechanisms to produce a target, expressed protein or biological target.” Going forward, investors will be on the lookout for developments in the construction, qualifications and commissioning of the new labs as significant value adds to both subsidiaries and the parent company. From there, the interest will fall into how the GMP facilities translate to additional revenue and profits. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire (BMW) San Francisco, California 415.949.5050 Office BioMedWire is part of the InvestorBrandNetwork.